The library will be closed between August 10, 2026 and August 16, 2026. During this period, it will be possible to upload publications, but all other services will be suspended.
Gergely, B.,
Vereb, M. A.,
Rebenku, I.,
Szöőr, Á.,
Vereb, G.:
Breaking the barrier: Synergistic 2B4.4-1BB signaling potentiates HER2-CAR NK cells to penetrate and destroy ADCC-resistant tumors.
Cancer Lett. 651, 1-9, (article identifier: 218534), 2026.
Kemenes, G.,
Rebenku, I.,
Vereb, G.,
Takács, L.:
Developing an ex vivo human cornea model for discovering the cellular interactions in simple limbal epithelial transplantation.
Invest. Ophthalmol. Vis. Sci. 66 (8), 1042, 2025.
Ujlaky-Nagy, L.,
Szöllősi, J.,
Vereb, G.:
EGFR-HER2 Transactivation Viewed in Space and Time Through the Versatile Spectacles of Imaging Cytometry - Implications for Targeted Therapy.
Cytom. Part A. 107 (3), 187-202, 2025.
Rebenku, I.,
Lloyd, C. B.,
Vereb, G.:
Measuring Molecular Interactions with Subcellular Resolution: Single-Cell FRET Using the Quantitative Three-Filterset (Intensity-Based) Approach.
In: The Surfaceome. Methods in Molecular Biology. Eds.: Matta C., Mobasheri A., Takács R, Humana, New York, NY, 171-189, 2025, (ISSN 1064-3745 ; vol 2908.) ISBN: 9781071644331
Gergely, B.,
Vereb, M. A.,
Rebenku, I.,
Vereb, G.,
Szöőr, Á.:
Targeting HER2-Positive Solid Tumors with CAR NK Cells: CD44 Expression Is a Critical Modulator of HER2-Specific CAR NK Cell Efficacy.
Cancers. 17 (5), 1-17, (article identifier: 731), 2025.
Barden, M.,
Elsenbroich, P. R.,
Haas, V.,
Ertelt, M.,
Pervan, P.,
Velas, L.,
Gergely, B.,
Szöőr, Á.,
Harrer, D. C.,
Bezler, V.,
Holzinger, A.,
Friis, R. U. W.,
Vereb, G.,
Schütz, G.,
Schoeder, C. T.,
Hombach, A. A.,
Abken, H.:
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function.
J. Immunother. Cancer. 12 (12), 1-14, (article identifier: 010208), 2024.
Nagy, L.,
Mezősi-Csaplár, M.,
Rebenku, I.,
Vereb, G.,
Szöőr, Á.:
Universal CAR T cells targeted to HER2 with a biotin-trastuzumab soluble linker penetrate spheroids and large tumor xenografts that are inherently resistant to trastuzumab mediated ADCC.
Front. Immunol. 15, 1-38, (article identifier: 1365172), 2024.
Barden, M.,
Holzinger, A.,
Velas, L.,
Mezősi-Csaplár, M.,
Szöőr, Á.,
Vereb, G.,
Schütz, G.,
Hombach, A. A.,
Abken, H.:
CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation.
Front. Immunol. 14, 1-13, (article identifier: 1110482), 2023.
Mezősi-Csaplár, M.,
Szöőr, Á.,
Vereb, G.:
CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells.
Cancers (Basel). 15 (12), 3081-3097, (article identifier: 3081), 2023.
Rebenku, I.,
Bartha, F.,
Katona, T.,
Zsebik, B.,
Antalffy, G.,
Takács, L.,
Molnár, B.,
Vereb, G.:
Taking molecular pathology to the next level: whole slide multicolor confocal imaging with the Pannoramic Confocal digital pathology scanner.
Cytom. Part A. 103 (3), 198-207, 2023.
Cserepes, M.,
Nelhűbel, G. A.,
Meilinger-Dobra, M.,
Herczeg, A.,
Türk, D.,
Hegedűs, Z.,
Svajda, L.,
Rásó, E.,
Ladányi, A.,
Csikó, K. G.,
Kenessey, I.,
Szöőr, Á.,
Vereb, G.,
Remenár, É.,
Tóvári, J.:
EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer.
Cancers (Basel). 14 (10), 1-15, (article identifier: 2407), 2022.
Mezősi-Csaplár, M.,
Szöllősi, J.,
Gottschalk, S.,
Vereb, G.,
Szöőr, Á.:
Cytolytic Activity of CAR T Cells and Maintenance of Their CD4+ Subset Is Critical for Optimal Antitumor Activity in Preclinical Solid Tumor Models.
Cancers (Basel). 13 (17), 1-19, (article identifier: 4301), 2021.
